Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
/AdlyxinTM) and iGlarLixi - EconoTimes)
- Royalty revenue of DKK 6.4 million / [Eur]0.9 million in Q2 2016 on Sanofi's sales of Lyxumia(r) (lixisenatide outside the U.S.)
- Recently, the U.S. FDA approved lixisenatide as AdlyxinTM to treat type 2 diabetes, and commercial launch by Sanofi in the U.S. is expected later in H2 2016
COPENHAGEN, Denmark, July 29, 2016 -- Zealand Pharma (Zealand), a biotechnology company, reports royalty revenue from Sanofi's global sales of Lyxumia(r) (lixisenatide outside the U.S.) of DKK 6.4 million / [Eur]0.9 million for the period from 1 April to 30 June 2016. For the first half of 2016, royalty revenue amounted to DKK 12.9 million / [Eur]1.7 million, a decrease of 3% compared to the same period in 2015. In its Q2 2016 earnings release today, Sanofi reported that sales of Lyxumia(r) were stable in H1 2016 versus the same period last year, measured at constant exchange rates.
Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment of patients with type 2 diabetes and was invented by Zealand. Global development and commercialization rights are licensed to Sanofi. Lixisenatide is approved under the proprietary name, Lyxumia(r), in more than 60 countries outside the U.S. and marketed by Sanofi in over 40 of these, including most EU countries (excluding France and Germany), Japan, Brazil, Mexico and India.
On 27 July 2016, lixisenatide was approved by the U.S. Food and Drug Administration (FDA) under the name of AdlyxinTM. U.S. commercial launch by Sanofi is expected later in H2 2016.
Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide insulin glargine 100 Units/mL (Lantus(r)), its worldwide most-prescribed basal insulin, for the treatment of type 2 diabetes. iGlarLixi is undergoing regulatory review in both the U.S. and Europe. On May 25, an Advisory Committee of the FDA recommended the approval of iGlarLixi and a regulatory decision by the FDA is expected in August 2016. In Europe, a regulatory decision is expected in Q1 2017.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer, Tel: +45 51 67 61 28, email: [email protected]
Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications, Tel: +45 50 60 36 89, email: [email protected]
